(IN BRIEF) The University of Warwick-coordinated OPTIMA trial, sponsored by University College London, has found that the Prosigna genomic test could help many patients with early-stage hormone-sensitive breast cancer avoid unnecessary chemotherapy without compromising outcomes. The trial followed more than … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, United Kingdom
Tagged Adrienne Morgan, American Society of Clinical Oncology, ASCO Annual Meeting, breast cancer, breast oncology, cancer recurrence, cancer research, Cardiff, chemotherapy, clinical trial, early stage breast cancer, gene test, genomic test, hormone therapy, hormone-sensitive breast cancer, Independent Cancer Patients’ Voice, Karen Bonham, lymph nodes, Major OPTIMA Trial Results Could Support Wider NHS Use of Genomic Testing to Reduce Chemotherapy Overtreatment, National Institute for Health and Care Research, NHS, NHS laboratories, Nice, NIHR, OPTIMA trial, Patient and Public Involvement, patient outcomes, personalised treatment, Professor Janet Dunn, Professor Rob Stein, Prosigna, radiotherapy, treatment decision-making, tumour biology, UCL, UCL Cancer Institute, University College London, University of Warwick, University of Warwick and UCL-Led Breast Cancer Trial Highlights Potential to Spare Thousands from Chemotherapy, University of Warwick-Coordinated OPTIMA Trial Shows Genomic Test Could Help Breast Cancer Patients Avoid Unnecessary Chemotherapy, unnecessary chemotherapy, Veracyte Inc, Warwick Clinical Trials Unit
(IN BRIEF) AstraZeneca announced positive interim Phase III VOLGA trial results showing that perioperative Imfinzi combined with neoadjuvant enfortumab vedotin significantly improved event-free survival and overall survival in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AstraZeneca, AstraZeneca Expands Immunotherapy Momentum in Bladder Cancer with Positive Phase III VOLGA Trial Readout, AstraZeneca oncology, bladder cancer, Cancer Immunotherapy, cancer recurrence, cancer treatment, cisplatin-ineligible patients, clinical trial results, CTLA-4, durvalumab, enfortumab vedotin, EV, event-free survival, Imfinzi, Imjudo, immunotherapy, MIBC, muscle-invasive bladder cancer, NIAGARA trial, NILE trial, oncology, oncology research, overall survival, PD-L1 inhibitor, Phase III Trial, POTOMAC trial, radical cystectomy, survival outcomes, Susan Galbraith, Thomas Powles, tremelimumab, urothelial carcinoma, VOLGA Phase III Results Position AstraZeneca’s Imfinzi Regimen as Promising New Option for Cisplatin-Ineligible Bladder Cancer Patients, VOLGA trial
(IN BRIEF) The Phase III RAMPART trial has demonstrated that combining the immunotherapy drugs durvalumab and tremelimumab after surgery significantly improves disease-free survival in patients with early-stage renal cell carcinoma (RCC). Led by the Medical Research Council Clinical Trials Unit … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca UK Limited, cancer recurrence, clinical trial, Combination Therapy, disease-free survival, durvalumab, ESMO 2025, European Society for Medical Oncology, ICR, immunotherapy, kidney cancer, Medical Research Council Clinical Trials Unit, MRC CTU, oncology research, precision medicine, Professor Angela Meade, Professor James Larkin, RAMPART trial, RAMPART trial confirms combination immunotherapy reduces recurrence risk in kidney cancer after surgery, RCC, renal cell carcinoma, The Institute of Cancer Research and Royal Marsden report breakthrough results in renal cancer immunotherapy trial, The Institute of Cancer Research London, The Royal Marsden Cancer Charity, The Royal Marsden NHS Foundation Trust, tremelimumab, UCL, University College London
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?